Glucose Transporters as a Target for Anticancer Therapy

Pliszka, Monika; Szablewski, Leszek

doi:10.3390/cancers13164184

Cited by 104 publications

(76 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most GLUT1 inhibitors cause cancer cell apoptosis only in synergy with another chemotherapeutic agent; a specific GLUT1 inhibitor is being studied for breast cancer (see references in cited review). 80 Notably, a specific GLUT5 inhibitor, N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA), did not affect glucose transport by GLUT1-4 or fructose transport by GLUT2 in humans 81 and decreased the viability of colon cancer cells. 35…”

Section: Glut5 Inhibitors In Amlmentioning

confidence: 99%

Fructose Metabolism and Acute Myeloid Leukemia

Kansal¹

2021

Explor Res Hypothesis Med

View full text Add to dashboard Cite

Section: Glut5 Inhibitors In Amlmentioning

confidence: 99%

Fructose Metabolism and Acute Myeloid Leukemia

Kansal¹

2021

Explor Res Hypothesis Med

View full text Add to dashboard Cite

“… 17 , 18 Hence, it has been proposed that glucose transporter expression may serve as a diagnostic and/or prognostic marker in cancer diseases 19 , and that these membrane carrier proteins may play a role in anticancer therapy. 16 , 20 …”

Section: Glucose Metabolism In Cancer Cellsmentioning

confidence: 99%

Glucose transporters as markers of diagnosis and prognosis in cancer diseases

Szablewski¹

2022

Oncol Rev

Self Cite

View full text Add to dashboard Cite

Glucose is a main metabolic substrate, which plays a role as a source of energy and a substrate in several processes. Cell membrane is lipophilic, whereas monosaccharides are hydrophilic. Therefore, lipid bilayer is impermeable for these substances and they need specific carrier proteins. Glucose metabolism in cancer cells differs from this process in normal cells. Cancer cells prefer the process of glycolysis, which generates less molecules of ATP than complete oxidative breakdown, therefore cancer cells need more molecules of glucose. Increased uptake of glucose is due to changes in expression of glucose transporters. Several glucose transporters are overexpressed in cancer cells, however, there are also observed decreased levels of these proteins in cancer cells. There are observed specific correlations between cancer and expression of glucose carrier proteins. Therefore, changes in expression of glucose transporters in cancers may be treated as a marker of diagnosis and/or prognosis for cancer patients.

show abstract

“…An increase in GLUT1–6 and 12 was reported in breast cancer ( 46 , 48 ) and glucose uptake by GLUT1 is considered an important mechanism in breast carcinogenesis and plays an important role in the early phase of breast cancer development ( 49 ). Upregulation of GLUT1, 3, and 4 is associated with cancer resistance and inhibition of GLUT may sensitize the anticancer effect of chemotherapeutic drugs ( 50 , 51 ). Several inhibitors of GLUT1 are reported in the literature and a non-exhaustive list is presented in Figure 3 .…”

Section: Glucose Metabolismmentioning

confidence: 99%

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas

et al. 2022

View full text Add to dashboard Cite

Breast cancer is characterized by considerable metabolic diversity. A relatively high percentage of patients diagnosed with breast carcinoma do not respond to standard-of-care treatment, and alteration in metabolic pathways nowadays is considered one of the major mechanisms responsible for therapeutic resistance. Consequently, there is an emerging need to understand how metabolism shapes therapy response, therapy resistance and not ultimately to analyze the metabolic changes occurring after different treatment regimens. The most commonly applied neoadjuvant chemotherapy regimens in breast cancer contain an anthracycline (doxorubicin or epirubicin) in combination or sequentially administered with taxanes (paclitaxel or docetaxel). Despite several efforts, drug resistance is still frequent in many types of breast cancer, decreasing patients’ survival. Understanding how tumor cells rapidly rewire their signaling pathways to persist after neoadjuvant cancer treatment have to be analyzed in detail and in a more complex system to enable scientists to design novel treatment strategies that target different aspects of tumor cells and tumor resistance. Tumor heterogeneity, the rapidly changing environmental context, differences in nutrient use among different cell types, the cooperative or competitive relationships between cells pose additional challenges in profound analyzes of metabolic changes in different breast carcinoma subtypes and treatment protocols. Delineating the contribution of metabolic pathways to tumor differentiation, progression, and resistance to different drugs is also the focus of research. The present review discusses the changes in glucose and fatty acid pathways associated with the most frequently applied chemotherapeutic drugs in breast cancer, as well the underlying molecular mechanisms and corresponding novel therapeutic strategies.

show abstract

Glucose Transporters as a Target for Anticancer Therapy

Cited by 104 publications

References 105 publications

Fructose Metabolism and Acute Myeloid Leukemia

Fructose Metabolism and Acute Myeloid Leukemia

Glucose transporters as markers of diagnosis and prognosis in cancer diseases

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas

Contact Info

Product

Resources

About